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ANTIVIRAL CHEMOTHERAPYt
As is well known, effective chemotherapy is available for a large number of
infectious diseases caused by bacteria multiplying extracellularly. Effective
chemotherapy is also available for a considerable number of infectious
diseases caused by intracellular agents. As shown in Table 1, typhoid fever
and tuberculosis provide examples of treatable diseases caused by non-
obligate intracellular bacterial agents. Diseases caused by rickettsiae, which
are obligate intracellular parasites (e.g., epidemic typhus and Rocky Moun-
tain spotted fever), respond satisfactorily to treatment with the various
tetracyclines or chloramphenicol. Results obtained earlier with p-amino-
benzoic acid were less impressive. Finally, treatment of psittacosis and
lymphogranuloma venereum with the various tetracyclines also gives satis-
factory results. Until recently the agents responsible for these and certain
other diseases were classified with viruses. Actually, the Chlamydozoaceae,
as this group of agents is now designated, seem to be more closely related
to rickettsiae than to the so-called true viruses.
The broad spectrum of effectiveness of the tetracyclines suggests that the
therapeutic effects may be obtained through interference with a metabolic
mechanism, probably biosynthetic, common to a wide variety of microbes.
On the other hand, the parasite selective activity of p-aminobenzoic acid,
penicillin, and sulfonamides emphasizes differences among the agents of
epidemic typhus, psittacosis, and lymphogranuloma venereum. It is likely
that these differences are also metabolic in nature. Available evidence indi-
cates that the chemotherapeutic agents listed in Table 1 reduce the rate of
multiplication of the various infectious agents. It is entirely possible, how-
ever, that in some instances the infecting agent is killed in the presence of
the chemotherapeutic compound and not merely retarded. As the result of
either mechanism, the number of infecting particles is kept relatively low.
When the number is kept below a critical value for a given infection,
symptoms and signs of disease may disappear or remain in abeyance.'3
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In sharp contrast, the multiplication of the so-called true viruses, i.e.,
agents of the size of vaccinia or smaller, is not slowed down or stopped by
any presently useful chemotherapeutic drug. Furthermore, the course of
disease caused by true viruses is not favorably altered by the administration
of any known chemotherapeutic agent, except when secondary bacterial
infection is also present.
It may be concluded that the site of multiplication is not a prime factor in*
determining chemotherapeutic effectiveness and that chemotherapy of
TABLE 1. CHEMOTHERAPY OF INFECTIOUS DISEASES CAUSED BY
INTRACELLULAR AGENTS
Infectious Useful
agents Diseases chemotherapeutic agents
Bacteria Typhoid fever Tetracyclines, chloramphenicol
Tuberculosis Streptomycin, isoniazid
Rickettsiae Epidemic typhus Tetracyclines, chloramphenicol,
Rocky Mountain spotted fever p-aminobenzoic acid
Chlamydozoaceae Psittacosis Tetracyclines, penicillin
Lymphogranuloma venereum Tetracyclines, sulfonamides
Viruses Mumps ............................
Infectious hepatitis ............................
diseases caused by numerous intracellular agents, excepting the viruses,
has already been accomplished.
The fact that a certain chemical substance inhibits one intracellular agent
but not another suggests that the modes of reproduction of the two agents
are different (Table 2). Available evidence, although scant, supports this
idea along three lines: (i) The size of the smaller viruses makes it unlikely
that they contain numerous complex enzyme systems. This may not apply
to the larger viruses. (ii) Metabolism of glutamate and pyruvate, independ-
ent of host cell metabolism, has been demonstrated in typhus rickettsiae."'
Thus it is likely that rickettsiae possess an energy-yielding mechanism of
their own. However, enzyme systems of carbohydrate metabolism were not
demonstrated in purified feline pneumonitis elementary bodies, although the
conditions of the experiment were similar to those under which typhus
rickettsiae were investigated.' Feline pneumonitis agent belongs with the
Chlamydozoaceae. Clearly, more work needs to be done in this area before
a definitive statement can be made on the presence or absence of an in-
dependent energy-yielding mechanism in Chlamydozoaceae. Attempts to
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demonstrate energy-yielding enzyme systems in true viruses have failed.
Apparently, viruses are dependent on host cells not only for building blocks
but also for the energy required in biosynthetic processes. (iii) Rickettsiae
multiply by binary fission. There is some evidence that at one stage in the
complex cycle of reproduction of Chlamydozoaceae, binary fission takes
place involving the so-called initial bodies which are about twice the size of
the elementary bodies.' When microbes multiply by binary fission, biosyn-
thesis of new materials, including nucleic acids and proteins, takes place
TABLE 2. CHARACTERISTICS OF INFECTIOUS AGENTS
Presence
Chemo- of energy-
Infectious therapy Size Intracellular yielding
agents available mIL parasitism metabolism Mode of multiplication
Bacteria + >500 Not obligate + Binary fission
Rickettsiae + 300 x 700 Obligate + Binary fission
Chlamydo-
zoaceae + 300-450 Obligate ? ? (Partly binary fission)
Viruses 0 15-250 Obligate 0 Eclipse -e reproduction
of hereditary material -)
stepwise development of
new particles.
inside particles which then proceed to divide. Division is preceded or
accompanied by distribution of particle constituents among daughter parti-
cles. In contrast, where evidence is available, it indicates that synthesis of
constituents of true viruses takes place outside, or rather in the temporary
absence of, a limiting membrane. As the synthesis of materials is completed,
component parts are formed and new particles assembled.
Thus it is likely that the reproduction of viruses is more intimately
dependent on host cell metabolism than is the multiplication of the larger
and more complex intracellular agents such as rickettsiae.
Many attempts have been made to inhibit virus multiplication without
causing damage to the host. Most such attempts have been unsuccessful,
probably because virus multiplication is so intimately dependent on host
cell metabolism. In what follows, the results of some of the more successful
experimental studies on viral chemotherapy will be described. Most of the
observations will concern agents capable of slowing or stopping virus multi-
plication. However, in a number of instances to be referred to, the mechan-
ism of action of the agent is not clearly established. Direct inactivating
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effects on the infectivity of virus particles may be operative in some cases.
Furthermore, certain compounds may exert an effect on tissue responses
which make up the composite picture of disease. In selecting agents for
review, two considerations were the main guides: (i) Promise shown in
animal experiments and (ii) Possibilities of improvement of chemothera-
peutic properties through chemical synthesis of new derivatives. A much
more complete review, covering chemotherapy of bacterial, plant, and ani-
mal viruses, has recently appeared.'8 Among the agents to be discussed,
TABLE 3. EXPERIMENTAL CHEMOPROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WITH NATURALLY OCCURRING SUBSTANCES
Test
Virus Animal Substance Author
Pneumonia Virus of Mouse Capsular polysaccharide of Horsfall and McCarty (1947) ;
Mice (PVM) K. pneumoniae Ginsberg and Horsfall (1951)8
MM Mouse MS-8450 (from Penicillium Powell et al. (1952, 1953)'-"
Semliki Forest Mouse stoloniferum)
Polio, Type 2 Mouse
Polio, Type 1 Monkey Cochran et al. (1954)6
Col SK Encephalomyelitis Mouse Helenine (from Penicillium Shope (1953)
"
Semliki Forest Mouse funiculosum)
Polio, Type 1 Monkey "' Cochran and Francis (1955)7
several represent so-called naturally occurring substances, whereas others
are synthetic chemicals.
Each of the naturally occurring substances listed in Table 3 is capable
under certain conditions of protecting a proportion of experimental animals
from death due to viral infection. However, it should be emphasized that
the conditions under which protection is demonstrable are such as to render
unlikely the possibility that these naturally occurring substances might be
useful in the treatment of viral disease in man.
PVM is a latent agent in mice, and so far as is known, does not cause
pneumonia in man. The capsular polysaccharide is effective only when
given by the same intranasal route as the virus.""' Intranasal instillation of
K. pneumoniae polysaccharide in amounts of 100 ,ug per mouse results in
the development of pulmonary lesions.8 In direct tests of chemotherapeutic
effectiveness the polysaccharide modified the course of PVM pneumonia in
the mouse and converted a virus infection which is rapidly fatal in control
animals into a mild illness from which treated animals recovered.8 This
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result was secured with a total dose of 20 ,ug of K. pneumoniae polysac-
charide per mouse when treatment was given two or three days after infec-
tion. At this dosage level the polysaccharide does not cause macroscopic
lung lesions. Before the substance was given, considerable virus reproduc-
tion had occurred and definite pneumonia was already present. After the
administration of the polysaccharide, further multiplication of the virus was
inhibited and soon ceased entirely. At the same time the progress of the
pneumonia was retarded and the lesions finally resolved. The K. pneu-
moniae polysaccharide had no effect on the multiplication of influenza A or
B virus in the mouse or in the chick embryo.'8
Most of the reported experiments with M5-8450, which is a crude filtrate
from culture of Penicillium stoloniferum, were on chemoprophylaxis rather
than therapy."' The viruses used were inoculated intraperitoneally or sub-
cutaneously or given by other peripheral routes. The available data indicate
that M5-8450 injected intraperitoneally 24 hours before inoculation of virus
prevents the death of a proportion of mice subsequently infected with MM,
Semliki Forest or poliovirus type 2. The effectiveness of M5-8450 is much
lower when it is administered by routes other than the intraperitoneal. It is
ineffective when given 4 to 6 hours after virus inoculation. Furthermore,
survivor mice, previously infected with MM or Semliki Forest virus and
treated, were found to be susceptible to new infection with homologous
virus.
In chemoprophylactic experiments in monkeys M5-8450 was injected in
repeated 25 ml. amounts intraperitoneally.6 The Mahoney strain of polio-
virus type 1 was given subcutaneously. In monkeys which received a total
dose of 100 ml. or more, the incidence of paralysis in control monkeys was
56 per cent (14 out of 25) and that in the treated group was 17 per cent
(4 out of 24). The day of onset of paralysis in control monkeys ranged from
7 to 32, whereas in the treated group it ranged from 24 to 42. Thus treat-
ment prolonged the incubation period. The authors concluded that in its
present state of development M5-8450 did not appear to have direct
therapeutic application.
Helenine is an acetone precipitate of an extract obtained from the culture
pellicle of Penicillium funiculosum.2" Mice that had been saved from either
Col SK or Semliki Forest virus infection by treatment with helenine fre-
quently were fully susceptible to reinfection by homologous virus. This was
especially true if the infecting dose of virus from which they had been
saved was a small one. With both viruses most significant effects were
obtained in treating infections initiated by 10 to 100 fatal doses of either
virus. Helenine had little if any effect on the course of infection when more
than 1,000 fatal doses were inoculated. Careful studies of the relationship
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between the amount of helenine injected and degree of protection obtained
showed that dependence of the protective effect on dosage was demonstrable
when relatively small amounts of helenine were used. A plateauing of
effectiveness was observed at larger doses, i.e., beyond a certain point,
increasing the dose did not increase the effect. For optimal effect helenine
had to be given within 3 hours of the time of infection.
TABLE 4. EXPERIMENTAL CHEMOPROPHYLAXIS OR THERAPY OF VIRAL
DISEASES WITH SYNTHETIC COMPOUNDS IN THE MOUSE
Virus Substance Author
Phenoxypyrimidines
Benzaldehyde thiosemicarbazones
Isatin thiosemicarbazones
,1
Russian Spring-Summer
Encephalitis
Col SK Encephalomyelitis
Influenza A, brain
Eastern Equine
Encephalomyelitis
Influenza B, lung
Aliphatic oxime thiosemicarbazones
2,6-Diaminopurine
2-Hydroxy-1,4-naphthoquinonimine
a-Aminosulfonic acids
Quinacrine (atebrin)
5.6-Dichloro-1-I3-D-ribofuranosyl-
benzimidazole
Thompson et al. (1951) ;4
Bauer (1955)'
Hamre et al. (1950, 1951) ;"-lo
Thompson et al. (1951, 1953)4°10
Thompson et al. (1953);"
Bauer (1955)'
Thompson et al. (1953)"
Moore and Friend (1951)"
Schnitzler et al. (1951);"
Jungeblut (1951)'
Ackermann (1952)'
Hurst et al. (1952)1
Tamm et al. (1954)'
Helenine, like M5-8450, exerts a preventive effect on paralytic polio-
myelitis due to the Mahoney strain of type 1 poliovirus in monkeys.' The
incidence of paralysis was reduced from 100 per cent in the control group to
18 per cent in the treated group. Although this material had marked chemo-
prophylactic activity, no significant chemotherapeutic effect was seen in
monkeys when treatment was withheld until the onset of the disease.
As Shope has pointed out, helenine may be related very closely to the
active principle in M5-8450 and may even be the same substance.' The
chemical nature of either material is not known. It has been shown that
helenine is non-dialyzable."
We turn now to results which have been obtained with synthetic com-
pounds. Table 4 lists studies with a variety of viruses and compounds in the
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mouse. In all of the studies listed with neurotropic viruses, protection from
death of a proportion of infected animals was clearly demonstrated. To
assess the importance of this remarkable finding it is necessary to take note
of the experimental conditions under which protection was demonstrable.
It is of considerable interest that, in studies with vaccinia virus, admin-
istration of compounds in diet or subcutaneously protected mice against
virus injected intracerebrally.'' Surviving animals which had been treated
with isatin thiosemicarbazone were immune to reinfection.8 Few data have
been reported on the toxicity of the compounds used in studies with the
vaccinia virus. Available data indicate that it was necessary to give nearly
toxic amounts of compounds in order to demonstrate protection. Likewise,
very little is known about the relationships between time of administration
of the compounds and the effect obtained. In none of these studies was a
chemotherapeutic effect demonstrated. Administration of the compound was
usually started before inoculation of virus. Where the chemical was given
after manifestations of disease had appeared, it failed to influence the infec-
tion in favor of the host. Another discouraging finding was that neither
benzaldehyde thiosemicarbazone nor isatin thiosemicarbazone was effective
against vaccinia virus infection in the rabbit."
It is of interest that 2,6-diaminopurine'9 and atebrin' were effective when
given 24 hours after the virus. In experiments with intraperitoneally in-
jected 2,6-diaminopurine, protection against Russian Spring-Summer en-
cephalitis was demonstrable when the virus was injected intraperitoneally
but not when the intracerebral route was used. Similar findings in regard to
route of administration and toxicity were made with 2-hydroxy-1,4-naph-
thoquinonimine in studies on Col SK encephalomyelitis in mice."' More-
over, 2-hydroxy-1,4-naphthoquinonimine was effective only when given
within one hour of virus inoculation. After treatment with this compound
surviving animals were susceptible to reinfection. a-Aminosulfonic acids
were effective in preventing encephalitis due to the neurotropic WS strain
of influenza A virus only when introduced intracerebrally.' The amount of
virus inoculated in these experiments apparently was small, since 13 to 20
per cent of untreated control mice also survived. The route of infection was
intracerebral. Data on toxicity of a-aminosulfonic acids in mice were not
given. Atebrin fed to mice inoculated intramuscularly or intracerebrally
with the virus of Eastern equine encephalomyelitis protected a significant
proportion of infected mice from death.' The most effective doses were near
the toxic limit, however, and no effect was seen when the drug was admin-
istered after infection of the nervous system had become established. It is
of considerable interest that in embryonated eggs atebrin had no effect on
infection with this virus.
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In our studies with influenza B virus in the mouse lung, we found that
5,6-dichloro-l-,8-D-ribofuranosylbenzimidazole, given in repeated intra-
peritoneal injections after intranasal inoculation of virus, retarded the multi-
plication of virus.'7 We found also (unpublished experiments) that this
compound prolonged survival time but did not protect mice from death
from pneumonia caused by the human influenza virus. Effective dose was
close to the toxic dose. As is well known, a vast amount of work has been
done with the influenza virus with the view of discovering effective in-
hibitors of this virus. Certain compounds have been found to inhibit multi-
plication of influenza virus in the chicken embryo without killing the
embryo. However, most of these compounds have shown no effect on multi-
plication of this virus in the mouse lung. Thus, 5,6-dichloro-1-f3-D-ribo-
furanosylbenzimidazole is among the few compounds which are capable of
inhibiting influenza virus multiplication in the mouse lung and prolonging
the survival time of infected mice.
The questions may be asked: (i) Why has it been relatively easy to
demonstrate protection against neurotropic viruses in the mouse? (ii) Why
has it thus far been impossible to protect mice against influenza virus pneu-
monia? No attempt will be made to answer these questions at this time, but
it is suggested that the particular organ or organ system involved in a virus
infection may condition the outcome of the experiment quite apart from
susceptibility of the virus to inhibition by a chemical compound. It would
seem desirable that more work be done on viral diseases involving organs
other than the brain and lung. Now that viral hepatitis in the mouse is a
fairly well-known disease,2' it would seem indicated that intensive chemo-
therapeutic studies be undertaken on this model since the viruses of human
hepatitis have failed to multiply and to cause disease in experimental
animals.
To sum up the results thus far obtained and to assess their bearing on
treatment of human or veterinary viral disease in the field, reference is made
to Hurst,'5 who has stated that the requirements for a drug which would be
useful in the field against arthropod-borne encephalitides are highly exacting
and that experiments with atebrin do not suggest that it will meet these
requirements. It would appear that this statement is applicable to all of the
compounds and infections which have been discussed.
Clearly, if effective chemoprophylaxis or therapy is to be achieved, a great
deal more work needs to be done in the laboratory. Continued screening of
mold and other filtrates and of synthetic chemical compounds may yield
effective agents, although returns from such efforts have not been abundant
so far. The so-called rational approach has provided equally meager returns,
probably because it has not been rational enough. We know essentially
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nothing about intermediates in the biosynthetic pathways of animal virus
nucleic acids or proteins beyond what we can guess. Yet it would seem that
knowledge of the intermediates and of enzymes involved in biosynthesis is
of the greatest importance for a rational approach to selective inhibition of
virus multiplication. That interference with single specific chemical reac-
tions involved in intracellular energy production does not provide a basis
for selective inhibition of virus multiplication has been amply demonstrated.
Such interference results in widespread disturbances in cellular metabolism
and damage to host cells.
NH2 NH2
Ci N
C1 IN H N N/ N
OH HI OC 1H H2C
I 0 0 I 0 HCOH IHCOH HCOH
I I I
CHAOH CH2OH CH20H
5,6-Dich1oro-1-0-D-3'ibo- 9-(3-D-RibO- 9-(3-D-2-Deoxyxibo-
furanosylbenzimidazole furanosyladenine fuvanosyladenine
(Inhibitor) (In RNA) (In DNA)
FIG. 1. Comparison of the structure of an inhibitor of virus multiplication with the
structures of two nucleosides.
The point of view which has been taken in our own work is that both
qualitative and quantitative differences may exist between the biosynthesis of
virus nucleic acids and host cell nucleic acids and that differences of either
kind may provide a basis for selective inhibition of virus multiplication with
appropriate compounds. However, approaches to chemical reactions which
may be qualitatively specific for the multiplying virus, e.g., the hypothetical
interlinking of nucleotides in a specific sequence to form virus nucleic acid,
are not obvious at the present time. It appears that it may be more profit-
able to attempt exploitation of probable quantitative differences in the bio-
synthetic demands of the virus versus the host cell. We assume that the
relative rates of synthesis ofviral and host cell nucleic acids may be different
and that differences may exist in respect to accessibility of sites of synthesis
to inhibitor molecules. It is obvious that through the use of suitable chemi-
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cal inhibitors, considerable insight might be gained into such differences.
Four years ago, in collaboration with Dr. Karl Folkers, we decided that
benzimidazole derivatives might prove to be suitable as selective inhibitors
of nucleic acid synthesis.' We proceeded to build up a body of knowledge
of structure-activity relationships with already available and new com-
pounds, and on the basis of such knowledge we made predictions as to what
0
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5,6-Dichloro-1-#-3D-ribofurmno,ylbenzimidozole
Molar concentration giving Activity
75 percent inhibition
benzimidazole 0.0035 5)
5,6-Dichloro-l-Q-D-
ribofuronosylbenzimidazole 0.000038
FIG. 2. Determination of the inhibitory activity of
benzimidazole derivatives on influenza B virus multi-
plication in the chorioallantoic membrane in vitro.
Data from Tamm et al." w
the structure of more ef-
fective compounds might
be. Starting with simple
alkyl derivatives of benzi-
midazole'" which showed
low activity and selectiv-
ity, we have progressed to
certain highly active and
moderately selective ribo-
sides of halogenated ben-
zimidazoles. " ', The
synthetic work has been
carried out by Dr. Karl
Folkers and Dr. Clifford
H. Shunk of the Research
Laboratories at Merck and
Co., Inc.
Figure 1 depicts the
structural similarity be-
tween one of the highly active inhibitors, the 8-D-ribofuranoside of 5,6-di-
chlorobenzimidazole, and adenine riboside. The similarity between the in-
hibitory riboside and adenine deoxyriboside is obviously less close. All of
these compounds possess a bicyclic skeleton, and in each, one of the ring
structures is imidazole. The pentose moiety is identical in the first two but
different in the third.
In our work it was important to determine the inhibitory activity and
selectivity of action, i.e., the activity-toxicity ratio, of derivatives with great
precision, unhampered by problems of absorption, transport, and excretion.
Also, since in most instances new compounds were used, it was important
to be able to make such determinations on small amounts of material.
A technique was devised for the quantitative study of influenza B virus
multiplication in the chorioallantoic membrane from embryonated chicken
eggs in vitro.'2' " Influenza virus was chosen mainly for reasons of experi-
mental convenience. Yield of virus in the presence of compounds at inhibi-
tory concentration was expressed in terms of per cent of yield in control
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cultures. It was plotted against concentration of compound used (Fig. 2).
The molar concentration required to cause 75 per cent inhibition of Lee
virus multiplication was determined for each compound. For unsubstituted
benzimidazole, this concentration is 0.0035 M. For purposes of comparison,
benzimidazole has been used as the reference compound with an arbitrarily
assigned Lee virus inhibitory activity of 1.
Figure 3 summarizes some important relationships between chemical
structure and virus inhibitory activity.>"8
"' As can be seen, the inhibitory
activity of benzimidazole derivatives increased with multiple substitution of
ci
ci Ii N~~~~~NN
5-Ch1oxo 5,5-Dichlopo 4,5,6-Trichlovo
NjOH7 N HOc Hjoj HNO% H\7 H4NNO7X
H2OjJI HCjOH 0 HCOH 0 HC~OHjj HCOHjI HSOHI
H JHCOH HCOH H C'j HC ' H
CHO2H H2C H2C CH220H CH20H CHzQH
1-0-D-RibO- 1-03-D-Ambino- 1-(3-D-Ribo- 1i--D-RibO- 1-a-D-RibO- 1-(-D-Ribo-
furanoside pyrcnoside pyranoside furanoside furanoside furanoside
FIG. 3. Chemical structure and influenza B virus inhibitory activity of benzimidazole
derivatives. Unsubstituted benzimidazole causes 75 per cent inhibition at 0.0035 M;
activity = 1. The encircled numbers below each compound refer to relative activity.
Data from Tamm,
n and Tamm et al.'-T
chlorine atoms in the benzenoid ring. Furthermore, the fl-D-ribofuranosides
of these chlorobenzimidazoles were much more active than the correspond-
ing simple chloro derivatives (3, 7, and 15 times, respectively). When the
glycosidic ring was changed from the 5-membered ribofuranoside to the 6-
membered ribopyranoside, the inhibitory activity dropped to Y6 of that
found for the ribofuranoside; in fact, the activity of the ribopyranoside was
almost identical with the activity of the simple 5,6-dichloro compound. The
activity of the arabinopyranoside was even lower, indicating that substitu-
tion of this pentose caused inactivation of the chloro compound. Comparison
of the a and ,8 forms of the ribofuranoside of trichlorobenzimidazole showed
that the pl-linked ribofuranoside is much more active than the a form.
It has been reported that the nucleic acid in influenza virus is of the
ribose type.2"'1 Thus, the highest virus inhibitory activity is obtained when
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the carbohydrate moiety at N1 is identical with that present in the nucleic
acid of influenza virus particles and when the benzenoid ring is loaded with
unnatural substituents.
Toxicity of compounds was studied by determining the concentration
required to cause macroscopic changes in the chorioallantoic membrane on
-40
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5,6-Dichlo.ro-1-(,-D3-.bofuranozylbenzimidazod
lfxlo-4
Toxic concentration Ratio -= 8 Virsus inhibitovy concentration
FIG. 4. Determination of influenza B virus inm
activity and tissue toxicity of benzimidazole
tives in the chorioallantoic membrane in vitro.
concentration = concentration causing 2+
scopic damage. Virus inhibitory concentrat
concentration causing 75 per cent inhibition o
multiplication. Data from Tamm."8'
Toxicity of compounds
was studied by determin-
ing the concentration re-
quired to cause macro-
scopic changes in the
chorioallantoic membrane
± on incubation in vitro.80,1
+ g' In the presence of toxic
i concentrations of com-
t pounds, the membranes
+ became flaccid and un-
0 folded, their color changed
.,+ C from pink to yellowish-
white, andthey lostweight.
Figure 4 shows the rela-
5 tionship between macro-
c scopic damage, reduced
oxygen uptake, and in-
hibitory activity. The ratio
of the concentration caus-
iibitory ingmacroscopic alterations
deriva- inthemembrane tothecon-
Toxic centration at which inhibi- macro-
tion = tion of virus multiplication
ft virus
occurs provides an indica-
tion of selectivity of action.
With key compounds, macroscopic and microscopic observations on mem-
branes were supplemented with studies on the effect of compounds on
oxygen uptake by host tissue, on proliferation of host cells in roller tube
cultures, and on toxicity in animals. Results of such studies were in line
with observations made on the chorioallantoic membrane in vitro.
In Table 5 the relationships between chemical structure and selectivity
of action""l4 are summarized. The 5-chloro compound, although 5 times
more active than unsubstituted benzimidazole (as was shown in Fig. 3),
was no more selective than the reference compound, as indicated by the
identical ratios of toxic to virus inhibitory concentration. Clearly, substitu-
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tion of the chlorine atom in the benzenoid ring caused a parallel increase in
virus inhibitory activity and toxicity. In contrast, substitution of /3-D-ribo-
furanose at Ni in the imidazole ring markedly increased virus inhibitory
activity without increasing toxicity to the same extent. Thus the 3-D-ribo-
furanose moiety confers selectivity of action on the molecule. The increase
in selectivity is moderate. As can also be seen, 8-D-arabinopyranose and
,8-D-ribopyranose failed to increase selectivity. Finally, to have this highly
desirable effect on the molecule, ribofuranose must be present in the
,a-linkage.
TABLE 5. CHEMICAL STRUCTURE AND SELECTIVITY OF ACTION OF
BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF INFLUENZA B
VIRUS MULTIPLICATION*
Derivatie *Ratio toxic concentration Derivative svrus inhibitory concentration
Benzimidazole 3
5-Chloro 3
5-Chloro-1-3-D-ribofuranosyl 8
5,6-Dichloro-1-,-D-arabinopyranosyI 3
5,6-Dichloro-l-,I-D-ribopyranosyl 3
5,6-Dichloro-l-P-D-ribofuranosyl 8
4,5,6-Trichloro-1-a-D-ribofuranosyl 4
4,5,6-Trichloro-1-P-D-ribofuranosyl 20
* Data from Tamm,wM
a and Tamm et al.'
These findings show that with certain compounds virus inhibitory activ-
ity and toxicity vary independently. Through appropriate modification of
the structure (i.e., substitution of t-D-ribofuranose), influenza virus in-
hibitory activity can be increased more than tissue toxicity. This selective
effect is not obtained with chlorine atoms. However, it should be possible
to replace chlorine atoms with some other substituents which, like
f3-D-ribofuranose, would confer selectivity on the molecule.
The special significance of the pentose moiety is emphasized by the
finding' that 8-D-ribofuranose, which is so important for selective inhibi-
tion of the ribonucleic acid-containing influenza virus, is not appropriate
for inhibition of the deoxyribonucleic acid-containing1"" vaccinia virus. We
have found that substitution of 83-D-ribofuranose in the chlorinated benzi-
midazole molecule causes no increase in inihibitory activity for vaccinia
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virus. In Table 6 this finding is contrasted with observations made earlier
with influenza virus.
It appears possible that for high activity against vaccinia virus and
perhaps other DNA containing viruses, deoxyribosides of suitable benzi-
midazoles may be required.
It should be apparent that selective inhibition of influenza virus multipli-
cation requires compounds of a special kind. Many of the benzimidazole
derivatives and a series of vitamin analogs, as well as benzene, and purine
derivatives which we have examined lack the properties which would
recommend them for more extensive virus studies. The very high influenza
virus inhibitory activity and the moderate selectivity of the 8-D-ribofurano-
TABLE 6. EFFECT OF THE RIBOSE MOIETY ON THE INHIBITORY ACTIVITY OF
CHLOROBENZIMIDAZOLES ON INFLUENZA B AND VACCINIA VIRUSES*
Ratio of inhibitory activities of bensimidazole derivatives
5-(or 6-)Chloro-1-,f-D-ribofuranosyl- 5,6-Dichloro-1-f-D-ribofuranosyl-
Virus 5-Chloro- 5,6-Dichloro-
Influenza B 2.7 6.7
Vaccinia 0.96 0.69
* Data from Tamm and Overman.'
sides stand out and suggest lines of investigation to develop still more
selective derivatives.
The available evidence suggests that 8-D-ribofuranosides of chlorobenzi-
midazoles interfere with metabolic processes involving ribofuranosides. It
is likely that synthesis of influenza virus RNA is inhibited on the nucleoside
level. That synthesis of host cell RNA may also be affected to some extent is
probable. The inhibitable processes take place early during the so-called
latent period of the cycle of influenza virus multiplication.
Finally, it should be emphasized that even if highly selective and potent
inhibitors of the multiplication of various viruses are found or developed,
their usefulness in the field may depend much on the characteristics of the
diseases in question. Factors such as length of the incubation period, site
or sites of infection, duration of illness, role of the immune response and
other mechanisms of the host in recovery, stability of the infectious agents,
and other factors will probably be of considerable importance in determining
the outcome of therapeutic intervention. Perhaps the outcome of such inter-
vention will depend more on how soon after infection it is feasible to start
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treatment than on any other factor. In certain viral infections the interval
between first symptoms and the time when maximal virus levels are reached
is short. In such situations prevention only may be feasible. A long incuba-
tion period, i.e., a long interval between exposure resulting in infection and
appearance of first symptoms, would greatly increase the chance of success-
ful prevention. Whether chemoprophylaxis were worthwhile would obvi-
ously depend on the severity of the disease, the attack rate, considerations
having to do with the effect prophylaxis might have on the development of
active immunity, and other factors.
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